Literature DB >> 21249322

Lactate dehydrogenase, Gleason score and HER-2 overexpression are significant prognostic factors for M1b prostate cancer.

Yoshiaki Yamada1, Kogenta Nakamura, Shigeyuki Aoki, Motoi Tobiume, Kenji Zennami, Yoshiharu Kato, Genya Nishikawa, Takahiko Yoshizawa, Youko Itoh, Akiko Nakaoka, Eri Yoshida, Tomoe Uchiyama, Nobuaki Honda.   

Abstract

It has not been elucidated whether certain types of M1b prostate cancer (M1b PC) are associated with a poor outcome. The present study retrospectively identified predictive factors related to the outcome of M1b PC. The subjects were 104 patients who attended our hospital and received a diagnosis of M1b PC. The observation period ranged from 4 to 122 months (median, 43 months). The parameters investigated were: T classification, N classification, Gleason score (GS), pretreatment prostate-specific antigen (PSA) level, extent of disease (EOD) grade, alkaline phosphatase (ALP), lactate dehydrogenase (LDH), calcium, and hemoglobin (Hb) levels, platelet count, and the status of HER-2 overexpression as determined with a Hercep Test(TM) Kit using initial needle biopsy specimens for diagnosis. Log-rank test and Cox univariate analysis identified the following factors with statistically significant differences: pretreatment PSA ≥ 192, N1, GS ≥ 8, EOD grade 3+4, high LDH, high ALP, low Hb, and HER-2 overexpression. Multivariate Cox proportional hazard analysis identified the factors GS ≥ 8, high LDH, and HER-2 overexpression with significant differences. The hazard ratio was 5.962, 2.465, and 2.907, respectively, and the probability value was P=0.0218, P=0.0207 and P=0.0090, respectively. When the subjects with GS ≥ 8, high LDH, and HER-2 over-expression were classified as the high-risk group, the 5-year cause-specific survival rate was 51.2, 29.6, and 20.0%, respectively. The present study showed that M1b PC patients with GS ≥ 8, high LDH, and HER-2 overexpression have a very poor outcome and thus, should be treated as a high-risk group requiring close follow-up.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21249322     DOI: 10.3892/or.2011.1154

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  7 in total

1.  Impact of nutritional status on the prognosis of patients with metastatic hormone-naïve prostate cancer: a multicenter retrospective cohort study in Japan.

Authors:  Teppei Okamoto; Shingo Hatakeyama; Shintaro Narita; Masahiro Takahashi; Toshihiko Sakurai; Sadafumi Kawamura; Senji Hoshi; Masanori Ishida; Toshiaki Kawaguchi; Shigeto Ishidoya; Jiro Shimoda; Hiromi Sato; Koji Mitsuzuka; Tatsuo Tochigi; Norihiko Tsuchiya; Yoichi Arai; Tomonori Habuchi; Chikara Ohyama
Journal:  World J Urol       Date:  2018-12-04       Impact factor: 4.226

2.  The predictive value of alkaline phosphatase and lactate dehydrogenase for overall survival in patients with esophageal squamous cell carcinoma.

Authors:  Xiao-Li Wei; Dong-Sheng Zhang; Ming-Ming He; Ying Jin; De-Shen Wang; Yi-Xin Zhou; Long Bai; Zhe-Zhen Li; Hui-Yan Luo; Feng-Hua Wang; Rui-Hua Xu
Journal:  Tumour Biol       Date:  2015-09-01

3.  Pre-treatment serum alkaline phosphatase and lactate dehydrogenase as prognostic factors in triple negative breast cancer.

Authors:  Bo Chen; Danian Dai; Hailin Tang; Xi Chen; Xiaohong Ai; Xiaojia Huang; Weidong Wei; Xiaoming Xie
Journal:  J Cancer       Date:  2016-11-25       Impact factor: 4.207

4.  Prognostic relevance of lactate dehydrogenase in advanced pancreatic ductal adenocarcinoma patients.

Authors:  Yuanyuan Xiao; Wen Chen; Zhihui Xie; Zhenyi Shao; Hua Xie; Guoyou Qin; Naiqing Zhao
Journal:  BMC Cancer       Date:  2017-01-06       Impact factor: 4.430

5.  Proteomic identification of the lactate dehydrogenase A in a radioresistant prostate cancer xenograft mouse model for improving radiotherapy.

Authors:  Jingli Hao; Peter Graham; Lei Chang; Jie Ni; Valerie Wasinger; Julia Beretov; Junli Deng; Wei Duan; Joseph Bucci; David Malouf; David Gillatt; Yong Li
Journal:  Oncotarget       Date:  2016-11-08

6.  Prognostic significance of elevated pretreatment systemic inflammatory markers for patients with prostate cancer: a meta-analysis.

Authors:  Hao Peng; Xiaogang Luo
Journal:  Cancer Cell Int       Date:  2019-03-25       Impact factor: 5.722

7.  Prognostic Value of Lactate Dehydrogenase in Second-Line Immunotherapy for Advanced Esophageal Squamous Cell Carcinoma.

Authors:  Yan Li; Kunlun Wang; Erjiang Zhao; Bingxu Li; Shenglei Li; Xiaotao Dong; Ling Yuan; Hui Yang
Journal:  Pathol Oncol Res       Date:  2022-06-03       Impact factor: 2.874

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.